Supernus Pharmaceuticals (NASDAQ:SUPN) Cut to “Buy” at Wall Street Zen

Wall Street Zen cut shares of Supernus Pharmaceuticals (NASDAQ:SUPN) from a strong-buy rating to a buy rating in a research report released on Saturday.

A number of other analysts also recently weighed in on the company. TD Cowen lifted their price target on Supernus Pharmaceuticals from $45.00 to $60.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. Piper Sandler raised Supernus Pharmaceuticals from a “neutral” rating to an “overweight” rating and raised their target price for the company from $40.00 to $65.00 in a report on Thursday, October 9th. Weiss Ratings restated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research report on Monday, December 29th. Bank of America started coverage on shares of Supernus Pharmaceuticals in a report on Wednesday, October 29th. They issued a “buy” rating and a $65.00 price target for the company. Finally, Zacks Research cut shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 8th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $61.60.

Supernus Pharmaceuticals Stock Performance

Shares of Supernus Pharmaceuticals stock opened at $48.78 on Friday. Supernus Pharmaceuticals has a one year low of $29.16 and a one year high of $57.65. The company has a market cap of $2.80 billion, a P/E ratio of -143.47, a PEG ratio of 0.51 and a beta of 0.71. The firm has a fifty day moving average of $48.84 and a two-hundred day moving average of $46.38.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its earnings results on Tuesday, November 4th. The specialty pharmaceutical company reported $0.46 earnings per share for the quarter, missing the consensus estimate of $0.82 by ($0.36). The firm had revenue of $170.00 million during the quarter, compared to analysts’ expectations of $175.82 million. Supernus Pharmaceuticals had a negative net margin of 2.81% and a positive return on equity of 11.51%. The firm’s revenue was up 9.3% on a year-over-year basis. During the same period in the previous year, the firm earned $0.69 EPS. As a group, equities analysts predict that Supernus Pharmaceuticals will post 2.38 earnings per share for the current year.

Insider Transactions at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, SVP Frank Mottola sold 20,000 shares of the firm’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $50.41, for a total transaction of $1,008,200.00. Following the completion of the transaction, the senior vice president directly owned 15,496 shares in the company, valued at approximately $781,153.36. This trade represents a 56.34% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Padmanabh P. Bhatt sold 710 shares of the company’s stock in a transaction dated Thursday, December 18th. The shares were sold at an average price of $44.44, for a total transaction of $31,552.40. Following the completion of the sale, the vice president directly owned 14,508 shares in the company, valued at $644,735.52. This trade represents a 4.67% decrease in their position. The SEC filing for this sale provides additional information. 8.80% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Supernus Pharmaceuticals

Several hedge funds have recently bought and sold shares of the stock. Rubric Capital Management LP purchased a new stake in shares of Supernus Pharmaceuticals in the second quarter valued at $21,908,000. Woodline Partners LP raised its stake in Supernus Pharmaceuticals by 63.5% in the 3rd quarter. Woodline Partners LP now owns 1,263,811 shares of the specialty pharmaceutical company’s stock valued at $60,398,000 after purchasing an additional 490,835 shares during the last quarter. Bank of America Corp DE raised its stake in Supernus Pharmaceuticals by 67.1% in the 3rd quarter. Bank of America Corp DE now owns 842,890 shares of the specialty pharmaceutical company’s stock valued at $40,282,000 after purchasing an additional 338,584 shares during the last quarter. UBS Group AG lifted its holdings in Supernus Pharmaceuticals by 137.6% in the 3rd quarter. UBS Group AG now owns 540,123 shares of the specialty pharmaceutical company’s stock valued at $25,812,000 after purchasing an additional 312,775 shares in the last quarter. Finally, Sofinnova Investments Inc. boosted its stake in shares of Supernus Pharmaceuticals by 53.5% during the 2nd quarter. Sofinnova Investments Inc. now owns 799,253 shares of the specialty pharmaceutical company’s stock worth $25,192,000 after purchasing an additional 278,575 shares during the last quarter.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.